The estimated Net Worth of Reid Mc Carthy is at least $58.6 Thousand dollars as of 19 August 2021. Reid Carthy owns over 500 units of Annovis Bio stock worth over $58,593 and over the last 3 years Reid sold ANVS stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Reid Carthy ANVS stock SEC Form 4 insiders trading
Reid has made over 1 trades of the Annovis Bio stock since 2021, according to the Form 4 filled with the SEC. Most recently Reid bought 500 units of ANVS stock worth $18,805 on 19 August 2021.
The largest trade Reid's ever made was buying 500 units of Annovis Bio stock on 19 August 2021 worth over $18,805. On average, Reid trades about 71 units every 0 days since 2021. As of 19 August 2021 Reid still owns at least 6,829 units of Annovis Bio stock.
You can see the complete history of Reid Carthy stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Reid Carthy's mailing address?
Reid's mailing address filed with the SEC is C/O ANNOVIS BIO, INC., 101 LINDENWOOD DR, SUITE 225, MALVERN, PA, 19355.
Insiders trading at Annovis Bio
Over the last 5 years, insiders at Annovis Bio have traded over $0 worth of Annovis Bio stock and bought 24,481 units worth $662,591 . The most active insiders traders include Michael B Hoffman, Maria Luisa Maccecchini, and Jeffrey Brian Mc Groarty. On average, Annovis Bio executives and independent directors trade stock every 138 days with the average trade being worth of $158,018. The most recent stock trade was executed by Maria Luisa Maccecchini on 6 February 2023, trading 52,755 units of ANVS stock currently worth $7,386.
What does Annovis Bio do?
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.
What does Annovis Bio's logo look like?
Complete history of Reid Carthy stock trades at Annovis Bio
Annovis Bio executives and stock owners
Annovis Bio executives and other stock owners filed with the SEC include:
-
Mark White,
Board Member -
Robert Whelan,
Board Member -
Claudine Bruck,
Board Member -
Maria Maccecchini,
Executive Board Member -
Michael Hoffman,
Chairman of the Board -
Reid Mc Carthy,
Director -
Jeffrey Brian Mc Groarty,
Chief Financial Officer -
Henry Iii Hagopian,
Chief Financial Officer